Vista AI Secures $29.5M in Series B Funding | 4DMedical Secures US$100+ Million Funding

Check out today’s featured companies who have recently raised a round of funding, and be sure to check out the full list of past healthcare IT fundings.

Vista AI Secures $29.5M in Series B Funding as Health Systems Back Automated MRI Scanning

Hospitals, Including Cedars-Sinai and Intermountain Health, Join Khosla Ventures and Others to Expand AI-Driven Scanning Across Anatomies

Vista AI, Inc., the leader in automated MRI scanning software for hospitals and imaging centers, today announced the closing of $29.5 million in Series B financing. New investors include Cedars-Sinai Health System, Intermountain Health, University of Utah Hospital System, Temple University/Fox Chase Cancer Center, and Tampa General Hospital, along with participation from Khosla Ventures, Bold Brain Capital, and other existing investors.

“Radiology is facing a critical bottleneck: demand for MRI far outstrips the supply of skilled technologists, overburdening staff and forcing delays for patients,” said Daniel Hawkins, CEO at Vista AI. “Vista AI is breaking through that barrier by automating the scanning process, enabling technologists to consistently and efficiently deliver high-quality imaging, regardless of location.”

The new financing will accelerate Vista AI’s growth. The company will build on its FDA-cleared and commercially available cardiac MRI platform by expanding into additional anatomies, including brain, prostate, and spine, once cleared by the FDA. With this broader portfolio, Vista AI will create the first comprehensive platform for automated MRI scanning—reducing scan variability and complexity while expanding access to advanced imaging. Vista AI is also extending its solution to include remote scanning services, enabling sites without prior cardiac MRI expertise or staffing to offer high-quality exams to their patients. Together, these capabilities are reshaping how and where advanced imaging can be delivered.

Vista AI has delivered measurable results at leading healthcare organizations. At Brigham and Women’s Hospital, Vista AI enabled 50% more cardiac MRI scan slots, eliminating a 28-day backlog and supporting next-day patient access without adding staff, scanners, or operating hours. At Radiology Regional, a Southwest Florida imaging chain, the automated platform reduced scan times by more than 50% and enabled technologists without prior cardiac MRI experience to reliably deliver exams with confidence…

Full release here, originally announced January 14th, 2026.

4DMedical Secures US$100+ Million Funding to Accelerate U.S. Expansion and Increase Technology Dominance in Software-Based Lung Imaging

Funding Will Scale Hospital Deployments for Groundbreaking CT:VQ Imaging Product, Strongly Advance R&D, Support Early Adopters at Stanford, Cleveland Clinic, University of Miami, UC San Diego Health, and More

4DMedical, the leader in software-based respiratory imaging technology, today announced US$100+ million (AU$150 million) in new institutional placement. The investment will primarily be leveraged to accelerate U.S. adoption of its class-leading “CT:VQ” product and significantly boost research and development—bolstering 4D’s technology lead in software-based lung imaging.

CT:VQ is 4DMedical’s FDA-cleared, SaaS technology that provides ventilation and perfusion insights from CT imaging. Within just four months of FDA clearance, CT:VQ was deployed by four elite U.S. academic medical centers: Stanford, Cleveland Clinic, University of Miami, and UC San Diego Health. These rapid adoptions reflect growing interest from clinicians seeking quantified, actionable, and functional information not available from traditional imaging–but increasingly vital to support diagnosis, treatment planning, and longitudinal monitoring.

“This is an extraordinarily important and validating event for multiple reasons,” says Andreas Fouras, PhD, 4DMedical Founder and CEO. “First, it reflects growing global recognition of the technological leadership of 4DMedical, including our groundbreaking products such as CT:VQ. And it recognizes both the commercial progress and even greater growth potential we have in the U.S. With this strong institutional backing and a strengthened balance sheet, we will scale adoption, accelerate R&D, deepen partnerships, and dominate the global marketplace for software-based lung imaging tools.”

What the Funding Enables for Hospitals and Health Systems

4DMedical will use the funding to expand U.S. availability of CT:VQ and support health systems with implementation at scale, including:

• Commercial expansion across U.S. academic medical centers and health systems, with a focus on real-world adoption and multidisciplinary use
• Customer success, training, and technical support to help integrate CT:VQ into existing clinical workflows and drive consistent utilization
• Ongoing research and development to expand 4DMedical’s technology leadership, product portfolio, and capabilities in functional lung imaging
• Operational scale and flexibility to support additional growth opportunities and sustained clinical partnerships

Following the raise, 4DMedical reported a pro forma cash position exceeding US$130+ million (AU$200+ million), which will support the company’s U.S. expansion strategy and growing installed base…

Full release here, originally announced January 20th, 2026.